New molecules as drug candidates for the treatment of upper and lower GI tract Ulcers

Current Pharmaceutical Design

Volumn 21, Issue 21, 2015, Pages 2993-3001

  Szabo, Sandor ^a   Tolstanova, Ganna ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

Author keywords

Angiogenic growth factors; Angiogenic steroids; Angiostatic steroids; Angiosteroids; BFGF; Crohn s disease; Dopamine; Gastric and duodenal ulcers; Inflammatory bowel diseases; PDGF; Pyrazole derivatives; Ulcerative colitis; VEGF

Indexed keywords

ALCOHOL; ANTIULCER AGENT; DOPAMINE; ENEMA; FIBROBLAST GROWTH FACTOR 2; NONSTEROID ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR; PYRAZOLE; STEROID; VASCULOTROPIN; ANGIOGENIC PROTEIN; PYRAZOLE DERIVATIVE;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DIGESTIVE SYSTEM ULCER; DUODENUM ULCER; GRANULATION TISSUE; HUMAN; INTESTINE ULCER; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH EROSION; STOMACH MUCOSA; ULCER HEALING; ULCERATIVE COLITIS; UNITED STATES; UPPER GASTROINTESTINAL TRACT; UPPER GASTROINTESTINAL TRACT ULCER; VIRAL GENE THERAPY; ANALOGS AND DERIVATIVES; ANIMAL; DUODENAL ULCER; STOMACH ULCER;

ANGIOGENIC PROTEINS; ANIMALS; ANTI-ULCER AGENTS; DOPAMINE; DUODENAL ULCER; HUMANS; PEPTIC ULCER; PYRAZOLES; STOMACH ULCER;

EID: 84931846557     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150514105026     Document Type: Article

References (102)

1. Swabb EA, Szabo S. Eds. Ulcer Disease: Investigation and Basis for Therapy. New York: Marcel Dekker, Inc. 1991.
2. Selye H. A syndrome produced by diverse nocuous agents. Nature 1936; 138: 132.
3. Selye H. The Physiology and Pathology of Exposure to STRESS. Montreal: ACTA, Inc., Medical Publishers, 1950.
4. Szabo S, Tache Y, Somogyi A. The legacy of Hans Selye and the origins of stress research: a retrospective 75 years after his landmark brief "Letter" to the Editor of Nature. Stress 2012; 15: 472-8.
5. Selye H. Perforated peptic ulcer during air-raid. Lancet 1943; 20: 252.
6. Stewart DN, Winser DMdeR. Incidence of perforated peptic ulcer. Effect of heavy air-raids. Lancet 1942; 1: 259-61.
7. Spicer CC, Stewart DN, Winser DMdeR. Perforated peptic ulcer during the period of heavy air-raids. Lancet 1944; 1: 14-5.
8. Tielemans MM, Eikendal T, Jansen JB, van Oijen MG. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010; 33: 443-53.
9. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32: 667-77.
10. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 321: 1273-5.
11. Szabo S. Hans Selye 70 years later: Steroids, stress ulcers and H. pylori. Arch Neurosci [Ideggyogy Szemle] 2014; 67: 85-8.
12. Liu Z, Yadav PK, Xu X, et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxity. J Leukoc Biol 2011; 89: 597-606.
13. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
14. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
15. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008; 456: 259-63.
16. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40: 1319-23.
17. Tolstanova G, Deng XM, French S, et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2012; 92: 9-21.
18. Kumar V, Fausto N, Abbas A. Robins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders 2005.
19. Rubin R, Strayer DS, Rubin E, McDonald JM. Rubin's Pathology. Baltimore: Lippincott Williams and Wilkins 2008.
20. Tolstanova G, Khomenko T, Deng XM, et al. Neutralizing anti- VEGF antibody reduces severity of experimental ulcerative colitis in rats. Direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: 749-57.
21. Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun 2006; 350: 147-50.
22. Tolstanova G, Khomenko T, Deng XM, Szabo S, Sandor ZS. New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis. Biochem Biophys Res Commun 2010; 399: 613-6.
23. Deng X, Szabo S, Khomenko T, Jadus MR, Yoshida M, Chen L. Detection of duodenal ulcer-associated genes in rats. Dig. Dis. Sci., 2008; 53: 375-84.
24. Szabo S, Chen L, Deng X, et al. Why gastrointestinal ulcers develop and do not heal? From New Ulcerogenic Chemicals to Novel Molecular Mediators and Ulcer Genes In: Mozsik G, Ed. Discoveries in Gastroenterology: From Basic Research to Clinical Perspectives 1960-2005. Budapest: Akademiai Kiado 2006; pp. 399-443.
25. Szabo S, Deng XM, Tolstanova G, et al. Angiogenic and antiangiogenic therapy for gastrointestinal ulcers: New challenges for rational therapeutic predictions and drug design. Curr Pharm Des 2011; 17: 1633-42.
26. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761-7.
27. Guth PH, Aures D, Paulsen G: Topical aspirin plus HCl gastric lesions in the rat. Cytoprotective effect of prostaglandin, cimetidine and probanthine. Gastroenterology 1979; 76: 88-93.
28. Szabo S, Gallagher G, Horner HC, et al. Role of the adrenal cortex in gastric mucosal protection by prostaglandins, sulfhydryls and cimetidine in the rat. Gastroenterology 1983; 85: 1384-90.
29. Szabo S, Trier JS, Frankel PW. Sulfhydryl compounds may mediate cytoprotection. Science 1981; 214: 200-2.
30. Szabo S. Peptides, sulfhydryls, and glucocorticoids in gastric mucosal defense: coincidence or connection? Gastroenterology 1984; 87: 228-9.
31. Lacy ER, Ito S. Rapid epithelial restitution of the rat gastric mucosa after ethanol injury. Lab Invest 1984; 51: 573-83.
32. Szabo S, Trier JS, Brown A, Schnoor J. Early vascular injury and increased vascular permeability in gastric mucosal injury caused by ethanol in the rat. Gastroenterology 1985; 88: 228-36.
33. Pihan G, Majzoubi D, Haudenschild C, Trier JS, Szabo S. Early microcirculatory stasis in acute gastric mucosal injury in the rat and prevention by 16, 16-dimethyl prostaglandin E2 or sodium thiosulfate. Gastroenterology 1986; 91: 1415-26.
34. Trier JS, Szabo S, Allan CH. Ethanol-i nduced dam- age to mucosal capillaries of rat stomach. Ultrastructural features and effects of prostaglandin F2 beta and cysteamine. Gastroenterology 1987; 92: 13-22.
35. Hauser J, Szabo S. Extremely long protection by pyrazole derivatives against chemically induced gastric mucosal injury. J Pharmacol Exp Ther 1991; 256: 592-8.
36. Szabo S. Pyrazole and thiozole derivatives for treatment of gastrointestinal ulcer disease. US patent #5, 223, 521 1993.
37. Szabo S. "Gastric cytoprotection" is still relevant. J Gastroenterol Hepatol 2014; 29(Suppl. 4): 124-32.
38. Gisbert JP, Calvet X. Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30: 791-815.
39. Kate V, Ananthakrishnan N, Tovey FI. Is Helicobacter pylori infection the primary cause of duodenal ulceration or a secondary factor? A review of the evidence. Gastroenterol Res Pract 2013, Article ID 425840, 8 pages.
40. Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol 2015; 172: 1-23.
41. Eisenhofer G, Aneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997; 82: 3864-71.
42. Vieira-Coelho MA, Soares-da-Silva P Dopamine formation, from its immediate precursor 3, 4-dihydroxyphenylalanine, along the rat digestive tract. Fundam Clin Pharmacol 1993; 7: 235-43.
43. Szabo S, Sandrock AW, Nafradi J, Maull EA, Gallagher GT, Blyzniuk A. Dopamine and dopamine receptors in the gut: Their possible role in duodenal ulceration. In: Kohasaka M, Shohmori J, Tsukada Y, Woodruff GN, Eds. Advances in Dopamine Research. Oxford: Pergamon Press 1982; pp. 165-70.
44. Li ZS, Schmauss C, Cuenca A, Ratcliffe E, Gershon MD. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: Analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci 2006; 26: 2798-807.
45. Szabo S, Reynolds ES, Unger SH. Structure-activity relations between alkyl nucleophilic chemicals causing duodenal ulcer and adrenocortical necrosis. J Pharmacol Exp Ther 1982; 223: 68-76.
46. Gallagher G, Brown A, Szabo S. Effect of dopamine-related drugs on duodenal ulcer induced by cysteamine or propionitrile: Prevention and aggravation may not be mediated by gastrointestinal secretory change in the rat. J Pharmacol Exp Ther 1987; 240: 883-9.
47. Szabo S, Horner HC, Gallagher GT. Drug-induced duodenal ulcer: Structure-activity correlations and pathogenesis. In: Pfeiffer CJ, Ed. Drugs and Peptic Ulcer. Boca Raton: CRC Press 1982; vol.2: pp. 55-74.
48. Szabo S. Dopamine disorder in duodenal ulceration. Lancet 1979; 2: 880-2.
49. Szabo S, Brown A, Pihan G, Dali H, Neumeyer JL. Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine). Proc Soc Exp Biol Med 1985; 180: 567-71.
50. Szabo S. Cho CH. From cysteamine to MPTP: structure-activity studies with duodenal ulcerogens. Toxicol Pathol 1988; 16: 205-12.
51. Szabo S, Horner HC, Maull H, Schnoor J, Chieuh CC, Palkovits M. Biochemical changes in tissue catecholamines and serotonin in duodenal ulceration caused by cysteamine or propionitrile in the rat. J Pharmacol Exp Ther 1987; 240: 871-8.
52. Horner HC, Szabo S. Differential effect of changing central and peripheral catecholamine levels in cysteamine-induced duodenal ulcer in the rat. Life Sci 1981; 29: 2437-43.
53. Ozdemir V, Jamal MM, Osapay K, et al. Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: Revisiting the "brain-gut axis" hypothesis in ulcer pathogenesis. Investig Med 2007; 55: 315-20.
54. Groĭsman SD, Karevina TG, Khokholia VP. Role of dopamine receptors in the mechanism of formation of stress-induced stomach lesions. Bull Eksp Biol Med 1984; 97(1): 57-60.
55. Belova EV. The effect of sulpirid in treatment of patients with gastric and duodenal erosions and ulcers. [Article in Russian]. Klin Med (Mosk) 2007; 85(7): 70-3.
56. Magro F, Vieira-Coelho MA, Fraga S, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5- hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 2002; 47: 216-24.
57. Magro F, Fraga S, Ribeiro T, et al. Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. Acta Physiol Scand 2004; 180: 379-86.
58. Magro F, Cunha E, Araujo F, et al. Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment. Dig Dis Sci 2006; 51: 2039-44.
59. Straub RH, Grum F, Strauch U, et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut 2008; 57: 911-21.
60. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis 2013; 50: 42-8.
61. Salat-Foix D, Tran K, Ranawaya R, Meddings J, Suchowersky O. Increased intestinal permeability and Parkinson disease patients: chicken or egg? Can J Neurol Sci 2012; 39: 185-8.
62. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011; 6(12): e28032.
63. Brahme F, Lindstrom C. A comparative radiographic and pathological study of intestinal vaso-architecture in Crohn's disease and in ulcerative colitis. Gut 1970; 11: 928-40.
64. Chidlow JH Jr, Langston W, Greer JJM, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169: 2014-30.
65. Danese S, Sans M, Motte CDL, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroeneterology 2006; 130: 2060-73.
66. Tolstanova G, Khomenko T, Deng X, et al. Neutralizing antivascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: 749- 57.
67. Jerkic M, Peter M, Ardelean D, et al. Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in Endoglin heterozygous mice. Inflamm Bowel Dis 2010; 16: 1859-70.
68. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585-95.
69. Coriat R, Mir O, Leblanc S, et al. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease. Inflamm Bowel Dis 2011; 17: 1632.
70. Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/ vascular endothelial growth factor. Nat Med 2001; 7: 569-74.
71. Sarkar C, Chakroborty D, Chowdhury UR, et al. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008; 14: 2502-10.
72. Basu S, Sarkar C, Chakroborty D, et al. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factormediated angiogenesis. Cancer Res 2004; 64: 5551-5.
73. Bhattacharya R, Sinha S, Yang SP, et al. The neurotransmitter dopamine modulates vascular permeability in the endothelium. J Mol Signal 2008; 3: 14.
74. Check JH, Katsoff B, Cohen R. Novel highly effective medical treatment of severe treatment refractory Crohn's disease using sympathomimetic amines: case report. Inflamm Bowel Dis 2010; 16: 1999-2000.
75. Check JH, Katsoff B, Cohen R. Case report showing that a woman with ulcerative colitis refractory to standard therapy responded well to the sympathomimetic amine dextroamphetamine sulfate. Inflamm Bowel Dis 2011; 17: 870-1.
76. Check JH, Amadi C, Kaplan H, Katsoff D. The treatment of idiopathic edema, a cause of chronic pelvic pain in women: effectively controlled chronic refractory urticaria--case reports. Clin Exp Obstet Gynecol 2006; 33: 183-4.
77. Glavin GB, Szabo S. Dopamine in gastrointestinal disease. Dig Dis Sci 1990; 35: 1153-61.
78. Folkman J, Shin Y. Angiogenesis. J Biol Chem 1992; 267: 10931- 4.
79. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
80. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997; 18: 4-25.
81. Szabo S, Folkman J, Vattay P, Morales RE, Kato K. In: Halter F, Garner A, Tytgat GNJ, Eds. Mechanisms of Peptic Ulcer Healing. London: Kluwer Academic Publishers 1991; pp. 139-50.
82. Szabo S, Folkman J, Vattay P, Morales RE, Pinkus GS, Kato K. Accelerated healing of duodenal ulcers by oral administration of a mutein of basic fibroblast growth factor in rats. Gastroenterology 1994; 106: 1106-11.
83. Folkman J, Szabo S, Stovroff M. McNeil P, Li W, Shing Y. Duodenal ulcer: Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991; 214: 414-26.
84. Satoh H, Shino A, Inatomi N, et al. Effect of rhbFGF mutein CS23 (TGP-580) on the healing of gastric ulcers induced by acetic acid in rats. Gastroenterology 1991; 100: A155.
85. Kusstatscher S, Sandor Z, Szabo S, et al. Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats. J Pharmacol Exp Ther 1995; 275: 456-61.
86. Szabo S, Sandor Z. Basic fibroblast growth factor and PDGF in GI diseases. Baillere's Clin Gastroenterol 1996; 10: 97-112.
87. Szabo S, Vincze A, Sandor ZS, et al. Vascular approach to gastroduodenal ulceration. New studies with endothelins and VEGF. Dig Dis Sci 1998; 43: 40S-5S.
88. Szabo S, Deng X, Khomenko T, et al. Angiogenic growth factors. In: Kaston J, Ed. Handbook of Biologically Active Peptides. New York: Elsevier 2013; pp. 1172-81.
89. Szabo S. Method for treating gastrointestinal ulcers with platelet derived growth factor (PDGF). US patent #5, 234, 908 1993.
90. Hull MA, Cullen DJ, Hudson N, et al. Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration. Gut 1995; 37: 610-2.
91. Nakamura M, Oda M, Inoue J, et al. Effect of basic fibroblast growth factor on reinervation of gastric microvessels. Possible relevance to ulcer recurrence. Dig Dis Sci 1995; 40: 1451-8.
92. Deng X, Szabo S, Khomenko T, Jadus MR, Yoshida M. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J Pharmacol Exp Ther 2004; 311: 982-8.
93. Sandor Z, Szeli D, Charette M, Szabo S. Platelet-derived growth factor (PDGF) accelerates the healing of experimental ulcerative colitis in rats. Gastroenterology 1995; 108(4): A887.
94. Sandor Z, Kusstatscher S, Szeli D, Szabo S. Effect of plateletderived growth factor in experimental colitis in rats. Orvosi Hetilap 1995; 136: 1059-61.
95. Paunovic B, Deng XM, Khomenko T, et al. Molecular mechanisms of bFGF effect on healing of ulcerative colitis in rats. J Pharmacol Exp Ther 2011; 339: 430-7.
96. Satoh H, Shino A, Sato F, et al. Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats. Jpn J Pharmacol 1997; 73: 59-71.
97. Szabo S, Shing Y, Folkman J, et al. Angiogenesis and growth factors in ulcer healing. In: Tai-Ping D. Fan, Elise C. Kohn, Eds. The New Angiotherapy, Totowa, New Jersey: Humana Press 2001, pp. 199-211.
98. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230: 1375-8.
99. Selye H. An attempt at a natural classification of the steroids. Nature 1943; 151: 662.
100. Selye H. Hormones and resistance. New York: Springer-Verlag, 1971.
101. Szabo S. Tetrahydro-S-21-Br and the use of angiogenic steroids. US patent #5, 239, 094 1993.
102. Szabo S, Vattay P, Morales RE, Saha B, Neumeyer JL, LeQuesne PW. Effect of a new class of steroids on healing of experimental chronic duodenal ulcers. Gastroenterology 1991; 100: A171.